• Company
• Evolution of ADCs… Enhertu prolongs OS in solid tumors
• by Son, Hyung-Min Jun 4, 2024 05:47am

• Company
• 'Jemperli,' a PD-1 inhibitor immunotherapy lands in Big 5
• by Eo, Yun-Ho Jun 4, 2024 05:46am

• Policy
• Takeda’s Zejula Tab receives marketing authorization in KOR
• by Lee, Hye-Kyung Jun 3, 2024 05:49am

• Company
• AbbVie’s Rinvoq is reimbursed for Crohn's Disease in KOR
• by Son, Hyung-Min Jun 3, 2024 05:49am

• Company
• 'Dupixent,' the final stages of reimb expansion for children
• by Eo, Yun-Ho Jun 3, 2024 05:48am

• Company
• Thrombocytopenia treatment market rises as blue ocean
• by Nho, Byung Chul Jun 3, 2024 05:48am

• Company
• Growing DME market…new drugs clinical trials·biosimilars
• by Son, Hyung-Min May 31, 2024 05:52am

• Company
• Adtralza becomes the 2nd reimbursed biological drug for AD
• by Son, Hyung-Min May 31, 2024 05:52am

• Policy
• Qarziba’s reimb standard has been set before approval
• by Lee, Tak-Sun May 31, 2024 05:51am

• Policy
• MFDS approves the orphan drug 'Pluvicto' for prostate cancer
• by Lee, Hye-Kyung May 31, 2024 05:51am